Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
EAI-432 offers a new approach to targeting mutant-EGFR driven non-small-cell lung cancer, say Dana-Farber researchers.
Treatment for metastatic disease may last indefinitely, amplifying the need for effective interventions.
Adding Tukysa to Kadcyla led to an improvement in progression-free survival, including for patients whose cancer had spread to the brain.
Fertility preservation and assisted reproductive technologies did not worsen outcomes for women with HR-positive breast cancer.
New test could change treatment for 1 in 3 patients with meningioma, a common form of brain tumor diagnosed in 42,000 Americans each year.
As a result of the investment in cancer research, NCI was in a strong position to make key early advances in the fight against HIV/AIDS.
The FDA is investigating the risk of new lymphoma among patients receiving the engineered T cells, but so far, cases are rare.
Better outcomes were achieved with combinations of experimental new drugs targeting common and rare tumour mutations.
New therapies tested delayed relapse and, in some cases, lengthened survival, for women with cervical, ovarian and endometrial cancers.
Researchers are investigating AI’s potential to transform cancer care and improve patient outcomes.
Early research in animals shows potential against cervical cancer and neuroblastoma.
Both approaches may offer a nonpharmaceutical option to use instead of or alongside opioids pain medication.
A UCSF trial tests precision radiation with immunotherapy as new treatment for advanced cases of metastatic prostate cancer.
However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.
An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.
Name change emphasizes the role of metabolic dysfunction in fatty liver disease.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.